Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3) > Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3):333-7

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3):333-7

DOI: 10.23736/S0392-0488.17.05043-X

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series

Sara TAMBONE 1, Maria C. FARGNOLI 1, Rodolfo CAPIZZI 2, Ketty PERIS 2

1 Department of Dermatology, University of L’Aquila, L’Aquila, Italy; 2 Institute of Dermatology, Catholic University of Rome, Rome, Italy


PDF


BACKGROUND: In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.
METHODS: Ten AK patients applied imiquimod 3.75% to the full face or scalp once-daily in two 2-week treatment cycles separated by a two-week treatment-free interval and were followed-up eight weeks later. Seven patients rated imiquimod 3.75% versus prior treatments (cryotherapy, photodynamic therapy, diclofenac sodium 3%, imiquimod 5%, ingenol mebutate).
RESULTS: The median clinical lesion count at baseline was 12.5. This increased to a median Lmax (maximum lesion count during treatment) of 22.5 as imiquimod 3.75% unmasked previously invisible subclinical lesions. At final follow-up, the median lesion count was 0. Local skin reactions such as erythema, scabbing and erosion occurred during each treatment cycle and were easy to manage. All patients considered imiquimod 3.75% easier to apply than prior treatments and 5 reported fewer or similar side effects.
CONCLUSIONS: In this cohort, imiquimod 3.75% effectively cleared clinical and subclinical lesions across the entire affected field and was well tolerated.


KEY WORDS: Keratosis, actinic - Therapeutics - Imiquimod

top of page